Panbela Therapeutics, Inc.
PBLA
$0.2603
-$0.0607-18.91%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -24.89% | -27.34% | -12.75% | -16.71% | 3.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.19% | 52.09% | -21.34% | -24.83% | -26.25% |
| Operating Income | -22.19% | -52.09% | 21.34% | 24.83% | 26.25% |
| Income Before Tax | -18.46% | -41.59% | 24.37% | 27.43% | 29.51% |
| Income Tax Expenses | 11.80% | 18.14% | -275.58% | -60.87% | -236.92% |
| Earnings from Continuing Operations | -18.68% | -42.23% | 25.07% | 27.72% | 30.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.68% | -42.23% | 25.07% | 27.72% | 30.31% |
| EBIT | -22.19% | -52.09% | 21.34% | 24.83% | 26.25% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 88.27% | 77.66% | 28.46% | -- | -- |
| Normalized Basic EPS | 94.65% | 84.18% | 36.48% | -- | -- |
| EPS Diluted | 88.27% | 77.66% | 28.46% | -- | -- |
| Normalized Diluted EPS | 94.65% | 84.18% | 36.48% | -- | -- |
| Average Basic Shares Outstanding | 6,590.28% | 16,728.17% | 27,172.31% | -- | -- |
| Average Diluted Shares Outstanding | 6,590.28% | 16,728.17% | 27,172.31% | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |